Salute e Benessere
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
"This is an important event for patients suffering from IgAN in Europe as Kinpeygo represents the first ever fully approved medication for this rare kidney disease. The long-term confirmatory trial met its eGFR endpoint with high statistical significance and we are delighted that the European Commission has granted a full approval for the broader population" said Renee Aguiar-Lucander , CEO.
Kinpeygo is marketed in in the EU and UK exclusively by Calliditas' commercial partner, STADA Arzneimittel AG.
The full marketing authorization for Kinpeygo covers the European Union (EU) member states as well as Iceland , Norway and Liechtenstein . Also, Kinpeygo's status as an orphan drug for a rare disease, subject to 10-year market exclusivity running until 2032, was confirmed by the Commission.
This approval triggers a milestone payment of ten million EUR to Calliditas, which will be recognized as revenue in the third quarter.
:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/calliditas-partner-stada-receives-european-commission-decision-for-full-approval-of-kinpeygo--for-th,c4019061
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/calliditas-partner-stada-receives-european-commission-decision-for-full-approval-of-kinpeygo-for-the-treatment-of-iga-nephropathy-302207686.html